214. Deputy John Brassil asked the Minister for Health the status of the implementation of the HSE’s best-value biologics process; if the HSE has plans to review this process to drive greater adoption of the designated best-value biological drug; if the HSE will expand this programme to further therapy areas in which a biosimilar drug is available here; and if he will make a statement on the matter. [48231/19]

The Health Service Executive has operational responsibility for best-value biological medicines, thus the matter has been referred to the HSE for their attention and direct reply to the Deputy.